Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Change in Cash: 2010-2025

Historic Change in Cash for Cumberland Pharmaceuticals (CPIX) over the last 15 years, with Sep 2025 value amounting to -$890,536.

  • Cumberland Pharmaceuticals' Change in Cash fell 794.06% to -$890,536 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.3 million, marking a year-over-year decrease of 117.41%. This contributed to the annual value of -$357,440 for FY2024, which is 75.11% up from last year.
  • Per Cumberland Pharmaceuticals' latest filing, its Change in Cash stood at -$890,536 for Q3 2025, which was down 190.98% from $978,868 recorded in Q2 2025.
  • In the past 5 years, Cumberland Pharmaceuticals' Change in Cash registered a high of $1.9 million during Q2 2023, and its lowest value of -$9.8 million during Q1 2022.
  • Over the past 3 years, Cumberland Pharmaceuticals' median Change in Cash value was $128,308 (recorded in 2024), while the average stood at -$414,657.
  • Over the last 5 years, Cumberland Pharmaceuticals' Change in Cash had its largest YoY gain of 666.90% in 2022, and its largest YoY loss of 5,879.04% in 2022.
  • Quarterly analysis of 5 years shows Cumberland Pharmaceuticals' Change in Cash stood at $1.2 million in 2021, then plummeted by 81.93% to $216,432 in 2022, then crashed by 186.10% to -$186,341 in 2023, then spiked by 368.02% to $499,430 in 2024, then slumped by 794.06% to -$890,536 in 2025.
  • Its last three reported values are -$890,536 in Q3 2025, $978,868 for Q2 2025, and -$2.9 million during Q1 2025.